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Introduction
Globally, malaria is the most widely spread infectious disease, with 228 million 
cases and an estimated 405,000 deaths in 2018. Unfortunately, the African region 
carries a disproportionately high share of the malaria burden.[1] For instance, in 
2018, almost 93% of malaria cases and 94% of deaths were from the African region. 
Plasmodium falciparum is responsible for 99.7% of malaria cases in Africa making 
this region the most affected in the world.[1]
The campaign of the World Health Organization (WHO) to eradicate malaria began 
in the 1950s. Despite this effort, drug-resistant parasites developed and resulted 
in the failure of response to chloroquine in endemic areas. The development of 
chloroquine-resistance prompted the WHO to introduce an artemisinin-based 
combination therapy (ACTs).[2]
Currently, the ACTs are recommended by the WHO as the first and second-line 
therapy of uncomplicated P. falciparum malaria and chloroquine-resistant P. vivax 
malaria.[1] 
However, recently emerging parasite resistance to artemisinin in Southeast Asian 
countries and Rwanda has raised concerns globally since there is no alternative drug 
to replace ACTs if they become ineffective.[3, 4]
This review article focuses mainly on artemisinin resistance because of its significant 
role in the treatment of P. falciparum malaria and what should be done to slow 
down artemisinin resistance. 
Artemisinin-based Combination Therapy (ACTs)
ACTs combine an artemisinin derivative with a partner drug (companion drugs). 
The artemisinin derivatives include dihydroartemisinin, artesunate, and artemether: 
partner drugs include lumefantrine, mefloquine, amodiaquine, sulfadoxine/
pyrimethamine, piperaquine, and chlorproguanil/dapsone.[5]
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Abstract
Malaria is a widely spread infectious disease and claims many lives annually in 
the African region. Therefore, prevention and effective therapy are significantly 
crucial for the successful reduction of malaria morbidity and mortality. However, 
recently emerging artemisinin-resistant parasites in Southeast Asia, South 
America, and Rwanda have raised concern globally. Studies have established that 
artemisinin-resistant is associated with a mutation in the Kelch13 (K13) propeller 
domain of malaria parasites. This mutation delays malaria parasite clearance from 
the bloodstream to more than three days following ACT’s therapy.
The objective of this paper is to alert authorities and researchers to the upcoming 
threat of artemisinin-resistant and recommend prevention strategies. Health 
authorities need to invest more in malaria prevention, enforcing existing 
laws, monitoring emerging resistance, and its impacts. Moreover, healthcare 
professionals can play a vital role by adhering to malaria treatment guidelines, 
avoiding monotherapy, and promoting antimalarial adherence 
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The ACTs have dual actions (immediate and long) 
against malaria parasites. While the fast-acting artemisinin 
derivative clears the parasites from the bloodstream within 
three days of ACT’s therapy, the long-acting partner drug 
clears the remaining parasites. This synergism has made 
ACTs the most efficacious antimalarial drugs with a 
profound record of morbidity and mortality reduction. [6]
Artemisinin Resistance (AR)
Artemisinin-resistance (AR) defines a delay in malaria 
parasite clearance from the bloodstream following ACTs 
treatment. Consequently, the artemisinin compound 
becomes less effective in clearing malaria parasites within 
three days.[4]
Recent studies have established that parasites’ resistance 
mechanism developed against the artemisinin compound 
is associated with a mutation in the Kelch13 (K13) 
propeller domain of malaria parasites, affecting only the 
parasites’ ring stage in humans.[4,7] Parasites carrying  K13 
have been reported in Southeast Asia, South America and 
Rwanda.[8, 9]
It is important to note that recent molecular studies have 
shown that the partial artemisinin-resistance in Rwanda 
emerged independently and did not come from South 
Asia.[4] The emerging artemisinin resistance in Rwanda 
was associated with poor treatment practice, inadequate 
adherence to the prescribed antimalarials, the widespread 
use of artemisinin-based monotherapy, and substandard 
drugs.[4]
It is important to note that ACTs are still significantly 
efficacious antimalarial drugs and can cure malaria as 
long as the partner drug is still effective.[4] However, the 
slow clearance of parasites from the bloodstream of a 
patient treated with ACTs adds significant dependence 
on a companion drug, increasing the parasite’s chances 
to develop resistance to ACTs and subsequently causing 
treatment failure. 
The main strength of ACTs is embodied in the dual-
effect as a deterrent mechanism against parasite resistance. 
Unfortunately, this defence mechanism began to crack 
in Southeast Asia, where ACTs have started to fail, and 
the emergence of mutated parasites in Rwanda. All these 
are signs of the inevitable development of artemisinin 
resistance. The world should think about alternative plans 
before the storm hits Africa, where the global burden of 
malaria morbidity and mortality is greatest.
Prevention strategy
The development of new treatment takes enormous efforts 
and resources. However, many strategies can be applied 
here, starting from the African health authorities and their 
partners, healthcare professions, and population. The 
health authorities need to focus more on fighting malaria 
through prevention, outlawing substandard drugs as well 
as enforcing existing laws, monitoring emerging resistance, 
and assessing their clinical impacts in collaboration with 
international partners. 
Moreover, healthcare professionals can play a vital role by 
adhering to malaria treatment protocols and guidelines, 
avoiding monotherapy, and promoting adherence to 
prescribed medications and reporting to authorities 
any suspicious cases of treatment failure. Finally, the 
population needs to continue prevention measures such as 
using mosquito nets and mosquito repellent, and adhering 
to a prescribed medication. 
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